Human telomerase active inhibitor protein and use thereof

A protein polypeptide and sequence technology, applied in the field of biotechnology and medicine, can solve the problems of limited protein and no protein found.

Inactive Publication Date: 2005-09-21
SHANGHAI INST OF BIOLOGICAL SCI CHINESE ACAD OF SCI
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the proteins related to telomerase inhibitory protein that have been found in the field so far are extremely limited, and no protein that interacts with LPTS and has telomerase inhibitory activity has been found.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Human telomerase active inhibitor protein and use thereof
  • Human telomerase active inhibitor protein and use thereof
  • Human telomerase active inhibitor protein and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0095] Embodiment 1: Cloning of MCRS2 protein cDNA

[0096] The interacting proteins of LPTS were screened by the conventional yeast two-hybrid technique, and the cDNA encoding LPTS was inserted into the pGilda vector (purchased from Clontech Company) for screening the human brain cDNA library (Clontech), according to the operating procedures provided by the company. The screened positive clones were verified and sequenced, and the sequences were compared with the GenBank database.

[0097] According to sequence information, design primer, carry out polymerase chain reaction (PCR), PCR reaction primer is: P1 (SEQ ID NO: 3), P2 (SEQ ID NO: 4), with the cDNA library plasmid of liver (GIBCO BRL company product ) as a template, PCR amplification to obtain MCRS2 gene cDNA. The PCR reaction conditions were 25 μl volume, pre-denaturation at 94°C for 4 minutes, cycle reaction at 94°C for 30 seconds, 50°C for 30 seconds, and 72°C for 2 minutes, for a total of 35 cycles. PCR products ...

Embodiment 2

[0099] Embodiment 2, recombinant expression and purification of MCRS2 protein

[0100] (a) Recombinant expression of MCRS2 protein

[0101] The MCRS2 nucleotide sequence obtained in Example 1 was digested with EcoRI and XhoI and loaded into the same digested 6×His-fusion expression vector pET-30 ((Novagen Company) to obtain the expression vector 6×His-MCRS2 .

[0102] The cDNA fragment (corresponding to 173-658 in SEQ ID NO: 1) containing MCRS2 N-terminal 162 amino acids was loaded into the GST-fusion expression vector pGEX-4T1 (Amersham Company) through EcoRI and XhoI restriction sites, and the obtained The plasmid was named GST-MCRS2-N.

[0103] Then the constructed plasmid was transformed into Escherichia coli BL21-DE3 to obtain MCRS2 / BL21-DE3 and MCRS2-N / BL21-DE3 transformed strains. After the obtained positive transformed strains were amplified, the plasmids were extracted and identified with corresponding restriction endonucleases, and confirmed by DNA sequencing.

...

Embodiment 3

[0110] Embodiment 3, the preparation of anti-MCRS2 protein antibody

[0111] Take 300 μg of purified 6×His-MCRS2 fusion protein, dissolve it in 0.5 mL PBS, add an equal volume of Freund’s complete adjuvant, mix well, and inject into the back of 2.0 kg male New Zealand white rabbits intradermally at multiple points. On the third day, the same amount of protein was mixed thoroughly with Freund's complete adjuvant again, and then intradermally injected in multiple points on the back. On the 28th day, the same amount of protein was mixed with Freund's incomplete adjuvant, and injected intradermally on the back to boost the immunization. After one week, the carotid artery was bled to collect blood, placed at 37°C for 3 hours, and placed at 4°C overnight to completely precipitate the serum, collected by centrifugation, aliquoted, and stored at -70°C. The specific detection method of the antibody is as follows: 1.5 μg of FLAG-MCRS2 plasmid was mixed with 10 μl of Lipofectamine (prod...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a new telomerase inhibition of active protein- MCRS2 protein, polynucleotides of coded MCRS2 protein and the method produced by recombination technology. The invention also discloses the application of MCRS2 protein and its coded sequence that the MCRS2 protein has the capacity of making the chromosome telomeric of liver cancer cells short and inhibiting telomerase activity.

Description

technical field [0001] The invention belongs to the field of biotechnology and medicine, in particular, the invention relates to a novel human telomerase activity inhibiting protein MCRS2 (microspherule protein 2) and its coding sequence. The present invention also relates to the use and preparation of MCRS2 polynucleotides and polypeptides. Background technique [0002] Existing studies have shown that 80% of tumor cells have telomerase activity, and inhibiting telomerase activity can make tumor cells age and die. [0003] LPTS is a known human telomerase inhibitory protein. The LPTS gene is located on the 8p23 segment of human chromosome 8, which is frequently deleted in a variety of malignant tumor cells. Studies have shown that the expression of LPTS in liver cancer tissues and liver cancer cell lines is extremely low or undetectable, so LPTS is related to liver cancer [C.Liao, M.J.Zhao, H.Song, K.Uchida, K.K.Yokoyama, T.P.Li, Identification of the gene for a novelliv...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61K38/57A61P35/00C07K14/435C07K14/47C07K16/18C12N15/12C12N15/63
Inventor 赵慕钧宋海李载平
Owner SHANGHAI INST OF BIOLOGICAL SCI CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap